Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Awantec's involvement in Malaysia's digital transformation, especially with the government, is a crucial part of the broader national strategy to enhance the digital economy and infrastructure. The MyDIGITAL initiative, which outlines Malaysia's digital transformation goals by 2030, encompasses accelerating digital adoption across industries, establishing a robust digital infrastructure, and developing digital talent to ensure inclusivity and competitiveness in the global digital economy
The Malaysian government plans to spend RM6 billion annually on digital transformation as part of a strategic initiative to save costs. This investment is aimed at enhancing efficiency, effectiveness, and transparency across government services by embracing digital technologies.
Digital transformation in Malaysia could potentially create up to RM257.2 billion in annual economic value by 2030, according to a study by AlphaBeta. This aligns with Malaysia's ambition to become a technologically advanced, digitally-driven nation and a regional digital economy leader by 2030, as outlined in the MyDigital initiative.
Mediforum Pharmaceutical Co., Ltd. (047920) (“Mediforum”) of South Korea and TauRx Pharmaceuticals Ltd. (“TauRx”) of Singapore announce that they signed a termsheet on June 12th 2020 giving Mediforum rights to acquire publishing, manufacturing, and intellectual property rights in Korea to TauRx’s LMTX. LMTX is, globally, the most advanced treatment targeting tau protein in Alzheimer’s disease. By signing this agreement, Mediforum plans to strengthen its position as a leading pharmaceutical company in Korea specializing in dementia.
"Conversely, we think M&A or in-licensing agreements may allow for earlier monetisation of Genting's stake, given that large pharmaceutical firms may have M&A interest in TauRx in order to possess the world's only effective Alzheimer's treatment.
"As a plus, M&A could allow TauRx to leverage on such firms' resources to expedite HMTM speed to market," it said in a note today.
Companies currently investing in TauRx Therapeutics are Temasek Holdings, Singapore’s state-owned investment company, Development Bank of Singapore and Canada’s Dundee Corp.
